Krawitt EL. Autoimmune Hepatitis. N Engl J Med. 2006;354:54–66.

Article  CAS  PubMed  Google Scholar 

Werner M, Wallerstedt S, Lindgren S, Almer S, Björnsson E, Bergquist A et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010;45:457–467.

Article  PubMed  Google Scholar 

Slooter CD, van den Brand FF, Lleo A, Colapietro F, Lenzi M, Muratori P et al. Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry. Hepatology. 2024;79:538.

Article  PubMed  Google Scholar 

Yoshizawa K, Matsumoto A, Ichijo T, Umemura T, Joshita S, Komatsu M et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatol Baltim Md. 2012;56:668–676.

Article  Google Scholar 

Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15:223–257.

Article  PubMed  Google Scholar 

Saleem S, Katragadda R, Weissman S, Bleibel W. Morbidity and mortality of infections in the cirrhotic patients: a US population-based study. Gastroenterol Hepatol Bed Bench. 2019;12:233–238.

PubMed  PubMed Central  Google Scholar 

EASL Clinical Practice Guidelines. Autoimmune hepatitis. J Hepatol. 2015;63:971–1004.

Article  Google Scholar 

Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatol Baltim Md. 2020;72:671–722.

Article  Google Scholar 

Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611–1629.

Article  CAS  PubMed  Google Scholar 

Pape S, Gevers TJG, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B et al. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2019;17:2068-2075.e2.

Article  CAS  PubMed  Google Scholar 

Plagiannakos CG, Hirschfield GM, Lytvyak E, Roberts SB, Ismail M, Gulamhusein AF et al. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study. J Hepatol. 2024;81:227–237.

Article  PubMed  Google Scholar 

Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis. Dig Dis Sci. 2017;62:2900–2907. https://doi.org/10.1007/s10620-017-4728-2

Article  CAS  PubMed  Google Scholar 

Hennes EM, Zeniya M, Czaja AlbertJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008 Jul;48(1):169–76.

Rahim MN, Miquel R, Heneghan MA. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep. 2020;2:100149.

Article  PubMed  PubMed Central  Google Scholar 

Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM, et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022 Apr;76(4):841–9.

de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974.

Article  PubMed  Google Scholar 

Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94:496–509.

Article  Google Scholar 

Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A et al. Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723–732.

Article  CAS  PubMed  Google Scholar 

Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR et al. Clinical, Biochemical, and Histological Remission of Severe Chronic Active Liver Disease: A Controlled Study of Treatments and Early Prognosis. Gastroenterology. 1972;63:820–833.

Article  CAS  PubMed  Google Scholar 

Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876–883.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Wu SS, Dong XQ, Wu Z, Zhao H, Wang GQ. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e18313.

Article  PubMed  PubMed Central  Google Scholar 

Taneja S, Mehtani R, De A, Mitra S, Rathi S, Verma N et al. Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital. J Clin Exp Hepatol. 2023;13:241–251.

Article  CAS  PubMed  Google Scholar 

Sandusadee N, Sukeepaisarnjaroen W, Suttichaimongkol T. Prognostic factors for remission, relapse, and treatment complications in type 1 autoimmune hepatitis. Heliyon. 2020;6:e03767.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muratori P, Lalanne C, Bianchi G, Lenzi M, Muratori L. Predictive factors of poor response to therapy in Autoimmune Hepatitis. Dig Liver Dis. 2016;48:1078–1081.

Article  PubMed  Google Scholar